Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma

As a benign intracranial tumor, craniopharyngioma(CP) treatment has always been considered a challenging clinical problem. Recently, BRAF V600E mutation in the pathogenesis of papillary craniopharyngioma (PCP) has been further revealed. Thus, BRAF inhibitors(BRAFi) serve as an applicable treatment for patients with PCP. Two patients with recurrent PCP were treated with combined BRAFi dabrafenib(150 mg, orally twice daily) and MEK inhibitors(MEKi) trametinib(2 mg, orally twice daily). A follow-up exceeding two years was conducted. We meticulously scrutinized the treatment's safety and efficacy profiles by delving into existing literature. One patient harboring a solid tumor achieved a complete tumor response devoid of any adverse events and encountered no recurrence over two years subsequent to discontinuation. Moreover, within a mere month of commencing targeted therapy (TG), the tumor demonstrates observable shrinkage. This finding substantiates the considerable potential inherent in targeted therapy for PCP cases marked by the somatic BRAF V600E mutation. Under specific conditions, individuals diagnosed with PCP can attain a complete tumor response following combined treatment with BRAFi/MEKi.